Author:
Wang Chuqiao,Wang Zeqi,Yao Tengteng,Zhou Jibo,Wang Zhaoyang
Abstract
Despite the remarkable success of immunotherapy in the treatment of melanoma, resistance to these agents still affects patient prognosis and response to therapies. Beta-2-microglobulin (β2M), an important subunit of major histocompatibility complex (MHC) class I, has important biological functions and roles in tumor immunity. In recent years, increasing studies have shown that B2M gene deficiency can inhibit MHC class I antigen presentation and lead to cancer immune evasion by affecting β2M expression. Based on this, B2M gene defect and T cell-based immunotherapy can interact to affect the efficacy of melanoma treatment. Taking into account the many recent advances in B2M-related melanoma immunity, here we discuss the immune function of the B2M gene in tumors, its common genetic alteration in melanoma, and its impact on and related improvements in melanoma immunotherapy. Our comprehensive review of β2M biology and its role in tumor immunotherapy contributes to understanding the potential of B2M gene as a promising melanoma therapeutic target.
Funder
National Natural Science Foundation of China
Reference91 articles.
1. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment;Marzagalli;Semin Cancer Biol,2019
2. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study;Robert;Lancet Oncol,2019
3. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma;Postow;N Engl J Med,2015
4. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma;Gide;Clin Cancer Res Off J Am Assoc Cancer Res,2018
5. Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma;Hofmann;J Cancer Res Clin Oncol,2011
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献